Biotech · Private company
Innate Pharma
Track this companyFree. Adds Innate Pharma to your Dealase workspace and tells you when its record changes.
Clinical trials113 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Anti-PD(L)1Phase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- IPH2101Phase 2 · Smoldering Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- IPH4102Phase 2 · Lymphoma, T-CellClinicalTrials.gov · fetched Nov 12, 2026
- IPH5201 + durvalumab + standard chemotherapyPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IPH6501Phase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- monalizumabPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- MonalizumabPhase 2 · Head and Neck NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- IPH4102Phase 1 · Cutaneous T-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- IPH4502Phase 1 · Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IPH5401 and DurvalumabPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- lacutamabPhase 1 · Peripheral T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 24, 2025ClinicalTrials.gov NCT06781983 · fetched Nov 12, 2026
- Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaPHASE1_PHASE2 · TERMINATED · started Mar 4, 2024ClinicalTrials.gov NCT06088654 · fetched Nov 12, 2026
- IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)PHASE2 · RECRUITING · started Jun 23, 2023ClinicalTrials.gov NCT05742607 · fetched Nov 12, 2026
- Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2PHASE1 · COMPLETED · started Mar 17, 2022ClinicalTrials.gov NCT05321147 · fetched Nov 12, 2026
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 2, 2020ClinicalTrials.gov NCT04590963 · fetched Nov 12, 2026
- IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaPHASE2 · COMPLETED · started May 22, 2019ClinicalTrials.gov NCT03902184 · fetched Nov 12, 2026
- IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Sep 7, 2018ClinicalTrials.gov NCT03665129 · fetched Nov 12, 2026
- Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckPHASE1_PHASE2 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02643550 · fetched Nov 12, 2026
- Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLPHASE1_PHASE2 · TERMINATED · started Nov 9, 2015ClinicalTrials.gov NCT02557516 · fetched Nov 12, 2026
- Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)PHASE1 · COMPLETED · started Oct 1, 2015ClinicalTrials.gov NCT02593045 · fetched Nov 12, 2026
- Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaPHASE2 · COMPLETED · started Sep 1, 2010ClinicalTrials.gov NCT01222286 · fetched Nov 12, 2026